Sarepta Therapeutics (SRPT) Delays Filing for Muscular Dystrophy Drug
October 27, 2014 at 09:25 AM EDT
Shares of Sarepta Therapeutics Inc. (SRPT) were trading down -7.86 or -33.36 percent to $15.70 per share in premarket trading on Monday. The company announced today it was delaying its filing for approval of its drug Eteplirsen for muscular dystrophy until 2015 following a request for more information on the drug from the FDA. Sarepta Read the full article... Read the rest of Sarepta Therapeutics (SRPT) Delays Filing for Muscular Dystrophy Drug at InvestorGuide.com .
